Stephen B. Maebius

Stephen B. Maebius is a partner at Foley & Lardner LLP with a practice concentrated on intellectual property matters in the life sciences sector. His work primarily involves pharmaceuticals, biotechnology, and chemical patents, stemming from his early career as a patent examiner in the USPTO's Biotechnology Group. Mr. Maebius's practice encompasses a wide range of IP services, including patent portfolio management, IP due diligence for major transactions, licensing, and litigation. He has advised on significant deals, such as Verona Pharma's acquisition by Merck & Co. and Transcend Therapeutics' sale to Otsuka Pharmaceutical Co., Ltd.

Based on the tracked cases, where he appeared exclusively for defendants, and his broader representative experience, Mr. Maebius's practice is focused on defending innovators and established companies. This is further evidenced by his extensive work representing patent owners before the Patent Trial and Appeal Board (PTAB). He has served as lead counsel in the successful defense of Orange Book-listed pharmaceutical patents against multiple inter partes review (IPR) challenges brought by generic petitioners and was co-counsel in the successful defense of a post-grant review involving a CRISPR Cpf1 patent.

Mr. Maebius has spent his career at Foley & Lardner, where he is a former Management Committee member and past chair of the firm's IP Practice. In addition to his PTAB victories, his experience includes a precedential Federal Circuit decision in Takeda Pharmaceutical Co. Ltd. v. John Doll concerning a double patenting rejection. He is the principal author of a book on IP due diligence and has testified before the FTC/DOJ on post-grant patent proceedings prior to the America Invents Act.

Mr. Maebius earned his J.D. from The George Washington University Law School and a B.S. in Biology from Cornell University. He is admitted to practice in the District of Columbia and Virginia, before the U.S. Supreme Court, the Federal Circuit, and the U.S. Patent and Trademark Office.